{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 64,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/35",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Complete Response Rate in Relapsed/Refractory Multiple Myeloma",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bb0d74e-4da7-493f-88f8-522faadfb4e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.72,
        "y": 0.3
      },
      "kind": "list",
      "text": "NXC-201 Class leading efficacy in multiple myeloma; NXC-201: low (4%) neurotoxicity grade 1-2; ~80% reduction in hospitalization cost",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e921698e-ad26-4ba0-8165-9f96261d0bb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "\"Yes/No BCMA\" refers to prior treatment with BCMA-targeted therapies. \"Overall\" includes a mix of Yes/No. Source: ...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e42d501-cf40-4cc7-b9b8-5bc536babf98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Multiple Myeloma, a $29 billion market by 2027",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f32561c-1554-4566-9b42-791ead720be4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "4379b6ef-202c-4d60-b113-cbff8a93330d",
      "evidence": "Comparing clinical efficacy and safety metrics against competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 19,
      "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}